Literature DB >> 20556554

Heart failure is preventable.

Jay N Cohn1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20556554     DOI: 10.1007/s11897-010-0015-7

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


× No keyword cloud information.
  10 in total

1.  Ventricular remodeling in heart failure: a credible surrogate endpoint.

Authors:  Marvin A Konstam; James E Udelson; Inder S Anand; Jay N Cohn
Journal:  J Card Fail       Date:  2003-10       Impact factor: 5.712

2.  Remodeling as an end-point in heart failure therapy.

Authors:  Jay N Cohn
Journal:  Cardiovasc Drugs Ther       Date:  2004-01       Impact factor: 3.727

3.  The prevention of heart failure--a new agenda.

Authors:  J N Cohn
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

4.  Is it the blood pressure or the blood vessel?

Authors:  Jay N Cohn
Journal:  J Am Soc Hypertens       Date:  2007 Jan-Feb

5.  Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg.

Authors: 
Journal:  JAMA       Date:  1970-08-17       Impact factor: 56.272

6.  Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance.

Authors:  J N Cohn
Journal:  Circulation       Date:  1973-07       Impact factor: 29.690

7.  The perindopril in elderly people with chronic heart failure (PEP-CHF) study.

Authors:  John G F Cleland; Michal Tendera; Jerzy Adamus; Nick Freemantle; Lech Polonski; Jacqueline Taylor
Journal:  Eur Heart J       Date:  2006-09-08       Impact factor: 29.983

8.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

Authors:  Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

9.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

Authors:  S Yusuf; B Pitt; C E Davis; W B Hood; J N Cohn
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

10.  Irbesartan in patients with heart failure and preserved ejection fraction.

Authors:  Barry M Massie; Peter E Carson; John J McMurray; Michel Komajda; Robert McKelvie; Michael R Zile; Susan Anderson; Mark Donovan; Erik Iverson; Christoph Staiger; Agata Ptaszynska
Journal:  N Engl J Med       Date:  2008-11-11       Impact factor: 91.245

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.